secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001493152-23-040786
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx Q3 net loss narrows to $1.4M on warrant gain; TIGeR-PaC trial advances
-------------------------------------------------------------------------------

- Net loss of $1.4M vs $2.1M YoY; includes $1.5M gain on fair value of common warrants.
- Cash and equivalents $3.2M as of Sept 30, 2023; shares outstanding 10.7M.
- R&D expense $1.6M, up 100% YoY, driven by Phase III TIGeR-PaC trial costs.
- Phase III TIGeR-PaC trial for pancreatic cancer continues after interim analysis recommended continuation.
- Collaboration with Imugene to expand TAMP platform into immunotherapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000149315223040786/0001493152-23-040786-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000149315223040786/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-040786

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer